Introduction
There has been an increased incidence of patients treated with congestive heart failure. The debate concerning the cardiovascular safety was started in 2007 when an analysis concerning risks associated with myocardial infarction was done. This debate has been going on since then, and recently the report from the US Senate Committee on Finance has provided more details about the analysis (Nissen, & Wolski 2010). Rosiglitazone is manufactured by the US pharmaceutical Company GlaxoSmithKline (GSK). This is a drug works as insulin through binding the peroxisome proliferator-activated receptors (PPAR) in fat cells thus making them respond more to insulin. Rosiglitazone is ...
